Payment overview · 2025
General Payments
$514.19
24 reported records · 12 companies
Healthcare provider profile · identity verified
Arvind Kumar Salwan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HESPERIA, CA · NPI 1437230190
Verified facts
What the public records show
CMS Open Payments records show Arvind Kumar Salwan, M.D. received $514.19 in general payments during 2025 across 24 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic, Rybelsus.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 343 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $131.37 | 25.6% | 6 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $75.81 | 14.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.37 | 13.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.24 | 6.8% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $34.43 | 6.7% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $31.46 | 6.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $31.34 | 6.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.27 | 4.7% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $23.45 | 4.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.38 | 4.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.37 | 3.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.70 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $474.35 | 22 |
| Education | $39.84 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $131.37 | 6 | 2025 |
Source payment records
|
|||||
| Encore Normalized: encore |
Device | Philips North America LLC | $75.81 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.79 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $34.43 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $31.46 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $31.34 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 343 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
343 | 56 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
231 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 949 | 251 |
| Amlodipine Besylate | Amlodipine Besylate | 704 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 669 | 163 |
| Lisinopril | Lisinopril | 630 | 166 |
| Metformin Hcl | Metformin Hcl | 624 | 160 |
| Omeprazole | Omeprazole | 533 | 139 |
| Trazodone Hcl | Trazodone Hcl | 507 | 98 |
| Gabapentin | Gabapentin | 480 | 142 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 428 | 122 |
| Losartan Potassium | Losartan Potassium | 376 | 100 |
| Furosemide | Furosemide | 352 | 97 |
| Ozempic | Semaglutide | 343 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 342 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 334 | 111 |
| Potassium Chloride | Potassium Chloride | 308 | 77 |
| Ibuprofen | Ibuprofen | 306 | 132 |
| Montelukast Sodium | Montelukast Sodium | 264 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 261 | 74 |
| Simvastatin | Simvastatin | 258 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 252 | 74 |
| Glipizide | Glipizide | 242 | 68 |
| Celecoxib | Celecoxib | 238 | 73 |
| Eliquis | Apixaban | 231 | 47 |
| Baclofen | Baclofen | 209 | 61 |
| Azithromycin | Azithromycin | 208 | 159 |
| Meloxicam | Meloxicam | 198 | 62 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 185 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 46 |
| Alendronate Sodium | Alendronate Sodium | 182 | 44 |
| Carvedilol | Carvedilol | 175 | 42 |
| Lovastatin | Lovastatin | 173 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 60 |
| Levofloxacin | Levofloxacin | 158 | 114 |
| Buspirone Hcl | Buspirone Hcl | 151 | 40 |
| Xarelto | Rivaroxaban | 148 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 139 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 38 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 137 | 29 |
| Allopurinol | Allopurinol | 133 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 133 | 102 |
| Fenofibrate | Fenofibrate | 133 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 132 | 33 |
| Atenolol | Atenolol | 131 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 126 | 51 |
| Tramadol Hcl | Tramadol Hcl | 121 | 34 |
| Ezetimibe | Ezetimibe | 113 | 27 |
| Mirtazapine | Mirtazapine | 113 | 36 |
| Methylprednisolone | Methylprednisolone | 111 | 78 |
| Naproxen | Naproxen | 111 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 28 |
| Jardiance | Empagliflozin | 101 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 101 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 101 | 24 |
| Nortriptyline Hcl | Nortriptyline Hcl | 100 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 97 | 60 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 26 |
| Pregabalin | Pregabalin | 91 | 17 |
| Spironolactone | Spironolactone | 90 | 23 |
| Famotidine | Famotidine | 89 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 85 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 21 |
| Benazepril Hcl | Benazepril Hcl | 83 | 20 |
| Meclizine Hcl | Meclizine Hcl | 83 | 32 |
| Sertraline Hcl | Sertraline Hcl | 81 | 19 |
| Estradiol | Estradiol | 80 | 25 |
| Folic Acid | Folic Acid | 80 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 32 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 71 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 70 | 40 |
| Januvia | Sitagliptin Phosphate | 70 | 16 |
| Prednisone | Prednisone | 70 | 44 |
| Trulicity | Dulaglutide | 70 | 11 |
| Clonidine Hcl | Clonidine Hcl | 68 | 19 |
| Nifedipine Er | Nifedipine | 68 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 15 |
| Glimepiride | Glimepiride | 64 | 15 |
| Methocarbamol | Methocarbamol | 62 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 24 |
| Memantine Hcl | Memantine Hcl | 56 | 13 |
| Colchicine | Colchicine | 55 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 16 |
| Fluconazole | Fluconazole | 54 | 35 |
| Ondansetron Odt | Ondansetron | 54 | 26 |
| Sulindac | Sulindac | 54 | 14 |
| Enalapril Maleate | Enalapril Maleate | 53 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 15 |
| Megestrol Acetate | Megestrol Acetate | 51 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 49 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 49 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 36 |
| Bupropion Xl | Bupropion Hcl | 46 | 15 |
| Levetiracetam | Levetiracetam | 46 | 14 |
| Linzess | Linaclotide | 46 | 13 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | 12 |
| Donepezil Hcl | Donepezil Hcl | 44 | 15 |
| Kerendia | Finerenone | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 41 | 17 |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Gemfibrozil | Gemfibrozil | 40 | 12 |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 32 |
| Nitroglycerin | Nitroglycerin | 37 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Acyclovir | Acyclovir | 36 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Finasteride | Finasteride | 33 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Creon | Lipase/Protease/Amylase | 30 | suppressed |
| Enulose | Lactulose | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | 13 |
| Topiramate | Topiramate | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Indomethacin | Indomethacin | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 26 | 11 |
| Imipramine Hcl | Imipramine Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 16 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Febuxostat | Febuxostat | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 11 |
| Promethazine Hcl | Promethazine Hcl | 24 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Premarin | Estrogens, Conjugated | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | 11 |
| Glyburide | Glyburide | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 18 |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 13 |
| Gentamicin Sulfate | Gentamicin Sulfate | 20 | 13 |
| Valsartan | Valsartan | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 16 |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Alogliptin | Alogliptin Benzoate | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | 11 |
| Methimazole | Methimazole | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $514.19 · 24 records | Bayer Healthcare Pharmaceuticals Inc. | Encore, FREESTYLE LIBRE 3, GLASSIA, Hillrom - Monarch Airway Clearance System, ISTURISA, KRYSTEXXA, Kerendia, Korlym, NURTEC ODT, Ocrevus Zunovo, Ozempic, Rybelsus, TEPEZZA, WINREVAIR, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error